Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat

Anushka V. Goonawardena, Lianne Robinson, Robert E. Hampson, Gernot Riedel*

*Corresponding author for this work

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

It is now well established that cannabinoid agonists such as Delta(9)-tetrahydrocannabinol (THC), anandamide, and WIN 55,212-2 (WIN-2) produce potent and specific deficits in working memory (WM)/short-term memory (STM) tasks in rodents. Although mediated through activation of CB1 receptors located in memory-related brain regions such as the hippocampus and prefrontal cortex, these may, in part, be due to a reduction in acetylcholine release (i.e., cholinergic hypofunction). To determine the interaction between cannabinoid and cholinergic systems, we exposed rats treated with WIN-2 or cholinergic drugs to a hippocampal-dependent delayed nonmatch to sample (DNMS) task to study STM, and recorded hippocampal single-unit activity in vivo. WIN-2 induced significant deficits in DNMS performance and reduced the average firing and bursting rates of hippocampal principal cells through a CB1 receptor-mediated mechanism. Rivastigmine, an acetylcholinesterase inhibitor, reversed these STM deficits and normalized hippocampal discharge rates. Effects were specific to 1 mg/kg WIN-2 as rivastigmine failed to reverse the behavioral and physiological deficits that were observed in the presence of MK-801, an NMDA receptor antagonist. This supports the notion that cannabinoid-modulated cholinergic activity is a mechanism underlying the performance deficits in DNMS. Whether deficits are due to reduced nicotinic or muscarinic receptor activation, or both, awaits further analysis.

Original languageEnglish
Pages (from-to)502-511
Number of pages10
JournalLearning & memory
Volume17
Issue number10
Early online date28 Sep 2010
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Delta(9)-tetrahydrocannabinol
  • brain slices
  • impairs spatial memory
  • 8-arm radial maze
  • receptor-mediated inhibition
  • sample performance
  • hippocampal acetylcholine-release
  • SR 141716A
  • in-vivo
  • endocannabinoid system

Cite this

Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat. / Goonawardena, Anushka V.; Robinson, Lianne; Hampson, Robert E.; Riedel, Gernot.

In: Learning & memory, Vol. 17, No. 10, 10.2010, p. 502-511.

Research output: Contribution to journalArticle

Goonawardena, Anushka V. ; Robinson, Lianne ; Hampson, Robert E. ; Riedel, Gernot. / Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat. In: Learning & memory. 2010 ; Vol. 17, No. 10. pp. 502-511.
@article{4aab1e28a83c46b09c9b5f30a2747048,
title = "Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat",
abstract = "It is now well established that cannabinoid agonists such as Delta(9)-tetrahydrocannabinol (THC), anandamide, and WIN 55,212-2 (WIN-2) produce potent and specific deficits in working memory (WM)/short-term memory (STM) tasks in rodents. Although mediated through activation of CB1 receptors located in memory-related brain regions such as the hippocampus and prefrontal cortex, these may, in part, be due to a reduction in acetylcholine release (i.e., cholinergic hypofunction). To determine the interaction between cannabinoid and cholinergic systems, we exposed rats treated with WIN-2 or cholinergic drugs to a hippocampal-dependent delayed nonmatch to sample (DNMS) task to study STM, and recorded hippocampal single-unit activity in vivo. WIN-2 induced significant deficits in DNMS performance and reduced the average firing and bursting rates of hippocampal principal cells through a CB1 receptor-mediated mechanism. Rivastigmine, an acetylcholinesterase inhibitor, reversed these STM deficits and normalized hippocampal discharge rates. Effects were specific to 1 mg/kg WIN-2 as rivastigmine failed to reverse the behavioral and physiological deficits that were observed in the presence of MK-801, an NMDA receptor antagonist. This supports the notion that cannabinoid-modulated cholinergic activity is a mechanism underlying the performance deficits in DNMS. Whether deficits are due to reduced nicotinic or muscarinic receptor activation, or both, awaits further analysis.",
keywords = "Delta(9)-tetrahydrocannabinol, brain slices, impairs spatial memory, 8-arm radial maze, receptor-mediated inhibition, sample performance, hippocampal acetylcholine-release, SR 141716A, in-vivo, endocannabinoid system",
author = "Goonawardena, {Anushka V.} and Lianne Robinson and Hampson, {Robert E.} and Gernot Riedel",
year = "2010",
month = "10",
doi = "10.1101/lm.1893710",
language = "English",
volume = "17",
pages = "502--511",
journal = "Learning & memory",
issn = "1072-0502",
publisher = "Cold Spring Harbor Laboratory Press",
number = "10",

}

TY - JOUR

T1 - Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat

AU - Goonawardena, Anushka V.

AU - Robinson, Lianne

AU - Hampson, Robert E.

AU - Riedel, Gernot

PY - 2010/10

Y1 - 2010/10

N2 - It is now well established that cannabinoid agonists such as Delta(9)-tetrahydrocannabinol (THC), anandamide, and WIN 55,212-2 (WIN-2) produce potent and specific deficits in working memory (WM)/short-term memory (STM) tasks in rodents. Although mediated through activation of CB1 receptors located in memory-related brain regions such as the hippocampus and prefrontal cortex, these may, in part, be due to a reduction in acetylcholine release (i.e., cholinergic hypofunction). To determine the interaction between cannabinoid and cholinergic systems, we exposed rats treated with WIN-2 or cholinergic drugs to a hippocampal-dependent delayed nonmatch to sample (DNMS) task to study STM, and recorded hippocampal single-unit activity in vivo. WIN-2 induced significant deficits in DNMS performance and reduced the average firing and bursting rates of hippocampal principal cells through a CB1 receptor-mediated mechanism. Rivastigmine, an acetylcholinesterase inhibitor, reversed these STM deficits and normalized hippocampal discharge rates. Effects were specific to 1 mg/kg WIN-2 as rivastigmine failed to reverse the behavioral and physiological deficits that were observed in the presence of MK-801, an NMDA receptor antagonist. This supports the notion that cannabinoid-modulated cholinergic activity is a mechanism underlying the performance deficits in DNMS. Whether deficits are due to reduced nicotinic or muscarinic receptor activation, or both, awaits further analysis.

AB - It is now well established that cannabinoid agonists such as Delta(9)-tetrahydrocannabinol (THC), anandamide, and WIN 55,212-2 (WIN-2) produce potent and specific deficits in working memory (WM)/short-term memory (STM) tasks in rodents. Although mediated through activation of CB1 receptors located in memory-related brain regions such as the hippocampus and prefrontal cortex, these may, in part, be due to a reduction in acetylcholine release (i.e., cholinergic hypofunction). To determine the interaction between cannabinoid and cholinergic systems, we exposed rats treated with WIN-2 or cholinergic drugs to a hippocampal-dependent delayed nonmatch to sample (DNMS) task to study STM, and recorded hippocampal single-unit activity in vivo. WIN-2 induced significant deficits in DNMS performance and reduced the average firing and bursting rates of hippocampal principal cells through a CB1 receptor-mediated mechanism. Rivastigmine, an acetylcholinesterase inhibitor, reversed these STM deficits and normalized hippocampal discharge rates. Effects were specific to 1 mg/kg WIN-2 as rivastigmine failed to reverse the behavioral and physiological deficits that were observed in the presence of MK-801, an NMDA receptor antagonist. This supports the notion that cannabinoid-modulated cholinergic activity is a mechanism underlying the performance deficits in DNMS. Whether deficits are due to reduced nicotinic or muscarinic receptor activation, or both, awaits further analysis.

KW - Delta(9)-tetrahydrocannabinol

KW - brain slices

KW - impairs spatial memory

KW - 8-arm radial maze

KW - receptor-mediated inhibition

KW - sample performance

KW - hippocampal acetylcholine-release

KW - SR 141716A

KW - in-vivo

KW - endocannabinoid system

U2 - 10.1101/lm.1893710

DO - 10.1101/lm.1893710

M3 - Article

VL - 17

SP - 502

EP - 511

JO - Learning & memory

JF - Learning & memory

SN - 1072-0502

IS - 10

ER -